Cargando…

Costs of Newly Funded Proton Therapy Using Time-Driven Activity-Based Costing in The Netherlands

SIMPLE SUMMARY: Proton therapy delivers more precise treatment compared with conventional radiotherapy. While this innovation entails investment costs, the information about the treatment costs per patient is limited. This information gap might prevent policymakers from making informed decisions. Th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Yi Hsuan, Blommestein, Hedwig M., Klazenga, Reinder, Uyl-de Groot, Carin, van Vulpen, Marco
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9856812/ https://www.ncbi.nlm.nih.gov/pubmed/36672465 http://dx.doi.org/10.3390/cancers15020516

Ejemplares similares

Medical Resource Use and Medical Costs for Radiotherapy-Related Adverse Effects: A Systematic Review
por: Chen, Yi Hsuan, et al.
Publicado: (2022)

A Practical Guide for Using Registry Data to Inform Decisions About the Cost Effectiveness of New Cancer Drugs: Lessons Learned from the PHAROS Registry
por: Blommestein, Hedwig M., et al.
Publicado: (2015)

Regulatory Approval, Reimbursement, and Clinical Use of Cyclin-Dependent Kinase 4/6 Inhibitors in Metastatic Breast Cancer in the Netherlands
por: Luyendijk, Marianne, et al.
Publicado: (2023)

Cost-Effectiveness Analysis of MammaPrint(®) to Guide the Use of Endocrine Therapy in Patients with Early-Stage Breast Cancer
por: Luyendijk, Marianne, et al.
Publicado: (2023)

Cost-Effectiveness of Abemaciclib in Early Breast Cancer Patients: One Size Fits All or Tailoring to Patients’ Needs?
por: Jongbloed, Elisabeth M, et al.
Publicado: (2023)

Cost-effectiveness of Novel Treatment Sequences for Transplant-Ineligible Patients With Multiple Myeloma
por: Blommestein, Hedwig M., et al.
Publicado: (2021)

Cost-effectiveness and budget impact of pembrolizumab+axitinib versus sunitinib in patients with advanced clear-cell renal cell carcinoma in the Netherlands
por: Xander, Nicolas S. H., et al.
Publicado: (2023)

Real-world cost-effectiveness of cetuximab in the third-line treatment of metastatic colorectal cancer based on patient chart review in the Netherlands
por: Uyl-de Groot, Carin A., et al.
Publicado: (2018)

Treatments and costs for recurrent and/or metastatic squamous cell carcinoma of the head and neck in the Netherlands
por: van der Linden, Naomi, et al.
Publicado: (2015)

The cost‐effectiveness of dapagliflozin compared to DPP‐4 inhibitors in the treatment of type 2 diabetes mellitus in the Netherlands
por: Van der Linden, N., et al.
Publicado: (2020)

Efficacy of first-line treatments for multiple myeloma patients not eligible for stem cell transplantation: a network meta-analysis
por: Blommestein, Hedwig M., et al.
Publicado: (2019)

Hospital-based or home-based administration of oncology drugs? A micro-costing study comparing healthcare and societal costs of hospital-based and home-based subcutaneous administration of trastuzumab
por: Franken, Margreet, et al.
Publicado: (2020)

Adjuvant Trastuzumab Therapy for Early HER2-Positive Breast Cancer in Iran: A Cost-Effectiveness and Scenario Analysis for an Optimal Treatment Strategy
por: Ansaripour, Amir, et al.
Publicado: (2017)

Potential health gains for patients with metastatic renal cell carcinoma in daily clinical practice: A real-world cost-effectiveness analysis of sequential first- and second-line treatments
por: De Groot, S., et al.
Publicado: (2017)

Cost-effectiveness of first line nivolumab-ipilimumab combination therapy for advanced non-small cell lung cancer: A systematic review and methodological quality assessment
por: Zaim, Remziye, et al.
Publicado: (2023)

Long-term Outcomes in Patients With Multiple Myeloma: A Retrospective Analysis of the Dutch Population-based HAematological Registry for Observational Studies (PHAROS)
por: Verelst, Silvia G.R., et al.
Publicado: (2018)

Cost-effectiveness of a Pharmacogenomic Test for Stratified Isoniazid Dosing in Treatment of Active Tuberculosis
por: Rens, Neil E, et al.
Publicado: (2020)

Unequal Access to Newly Registered Cancer Drugs Leads to Potential Loss of Life-Years in Europe
por: Uyl-de Groot, Carin A., et al.
Publicado: (2020)

A Systematic Review of Cost-Effectiveness Analyses of Novel Agents in the Treatment of Multiple Myeloma
por: Seefat, Maarten R., et al.
Publicado: (2021)

Use of data-mining to support real-world cost analyses: An example using HER2-positive breast cancer in Iran
por: Ansaripour, Amir, et al.
Publicado: (2018)

Cost-effectiveness analysis of the first-line EGFR-TKIs in patients with non-small cell lung cancer harbouring EGFR mutations
por: Holleman, Marscha S., et al.
Publicado: (2019)

Systematic reviews as a “lens of evidence”: Determinants of cost‐effectiveness of breast cancer screening
por: Mandrik, Olena, et al.
Publicado: (2019)

High Hospital-related Costs at the End-of-life in Patients With Multiple Myeloma: A Single-center Study
por: Bennink, Christine, et al.
Publicado: (2023)

Cost-Effectiveness of Hypothetical New Cancer Drugs in Patients with Advanced Small-Cell Lung Cancer: Results of a Markov Chain Model
por: Uyl-de Groot, Carin A, et al.
Publicado: (2006)

Health-care costing in the Netherlands
por: Meijer, R, et al.
Publicado: (2010)

Changes in survival in de novo metastatic cancer in an era of new medicines
por: Luyendijk, Marianne, et al.
Publicado: (2023)

Extrapolating empirical long-term survival data: the impact of updated follow-up data and parametric extrapolation methods on survival estimates in multiple myeloma
por: Bakker, LJ, et al.
Publicado: (2023)

The cost-effectiveness of (18)FDG-PET in selecting patients with suspicion of recurrent laryngeal carcinoma after radiotherapy for direct laryngoscopy
por: van Hooren, Addy C. G., et al.
Publicado: (2008)

Estimate on costs and funding of L3
por: CERN. Geneva. LEP Experiments Committee
Publicado: (1982)

Increasing Costs of Skin Cancer due to Increasing Incidence and Introduction of Pharmaceuticals, 2007–2017
por: NOELS, Eline, et al.
Publicado: (2020)

Hospital costs and cosmetic outcome of benign and high-risk breast lesions managed by vacuum-assisted excision versus surgical excision
por: van de Voort, Elles MF, et al.
Publicado: (2022)

Costing the outpatient rehabilitation services: time-driven activity-based costing approach
por: Mohammadpour, Farzaneh, et al.
Publicado: (2022)

A cost of illness study of hypoglycaemic events in insulin-treated diabetes in the Netherlands
por: de Groot, Saskia, et al.
Publicado: (2018)

Actuarial Cost Analysis for options on the Future of the Fund
Publicado: (2016)

Cost Effectiveness of Gastroprotection with Proton Pump Inhibitors in Older Low-Dose Acetylsalicylic Acid Users in the Netherlands
por: Chau, Sek Hung, et al.
Publicado: (2017)

Cost‐effectiveness of Anti‐CD19 chimeric antigen receptor T‐Cell therapy in pediatric relapsed/refractory B‐cell acute lymphoblastic leukemia. A societal view
por: Thielen, Frederick W., et al.
Publicado: (2020)

Precision, time, and cost: a comparison of three sampling designs in an emergency setting
por: Deitchler, Megan, et al.
Publicado: (2008)

Dealing with Time Estimates in Hospital Cost Accounting: Integrating Fuzzy Logic into Time-Driven Activity-Based Costing
por: Koster, Fiona, et al.
Publicado: (2023)

Rethinking the cost of healthcare in low-resource settings: the value of time-driven activity-based costing
por: McBain, Ryan K, et al.
Publicado: (2016)

A pragmatic method for costing implementation strategies using time-driven activity-based costing
por: Cidav, Zuleyha, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_0o1vetpskiok9armndlohv2gnf